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Background. This intercontinental study aimed to study gram-negative rod (GNR) resistance in hematopoietic stem cell trans-
plantation (HSCT).
Methods. GNR bacteremias occurring during 6 months post-HSCT (February 2014–May 2015) were prospectively collected, 
and analyzed for rates and risk factors for resistance to fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbap-
enems), carbapenems, and multidrug resistance.
Results. Sixty-five HSCT centers from 25 countries in Europe, Australia, and Asia reported data on 655 GNR episodes and 704 
pathogens in 591 patients (Enterobacteriaceae, 73%; nonfermentative rods, 24%; and 3% others). Half of GNRs were fluoroquinolone 
and noncarbapenem resistant; 18.5% carbapenem resistant; 35.2% multidrug resistant. The total resistance rates were higher in allo-
geneic HSCT (allo-HSCT) vs autologous HSCT (auto-HSCT) patients (P <  .001) but similar in community-acquired infections. 
Noncarbapenem resistance and multidrug resistance were higher in auto-HSCT patients in centers providing vs not providing 
fluoroquinolone prophylaxis (P < .01). Resistance rates were higher in southeast vs northwest Europe and similar in children and 
adults, excluding higher fluoroquinolone- and β-lactam/β-lactamase inhibitor resistance rates in allo-HSCT adults. Non-Klebsiella 
Enterobacteriaceae were rarely carbapenem resistant. Multivariable analysis revealed resistance risk factors in allo-HSCT patients: 
fluoroquinolone resistance: adult, prolonged neutropenia, breakthrough on fluoroquinolones; noncarbapenem resistance: hospi-
tal-acquired infection, breakthrough on noncarbapenems or other antibiotics (excluding fluoroquinolones, noncarbapenems, car-
bapenems), donor type; carbapenem resistance: breakthrough on carbapenem, longer hospitalization, intensive care unit, previous 
other antibiotic therapy; multidrug resistance: longer hospitalization, breakthrough on β-lactam/β-lactamase inhibitors, and car-
bapenems. Inappropriate empiric therapy and mortality were significantly more common in infections caused by resistant bacteria.
Conclusions. Our data question the recommendation for fluoroquinolone prophylaxis and call for reassessment of local empiric anti-
biotic protocols. Knowledge of pathogen-specific resistance enables early appropriate empiric therapy. Monitoring of resistance is crucial.
Clinical Trials Registration. NCT02257931
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Hematopoietic stem cell transplantation (HSCT) is increasingly 
used to cure a wide range of malignant and nonmalignant dis-
orders [1]. Growing antimicrobial resistance, especially among 
gram-negative rods (GNRs), negatively affects prognosis and 
can influence eligibility for HSCT [2]. Treatment options remain 
limited [3], although the proportion of GNRs among infec-
tious etiologies is rising [4–6] and resistant GNR infections are 
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associated with delay in giving appropriate therapy, increased 
mortality, and high risk of infection recurrence [7–9]. 
Several studies, mainly limited to single centers or countries, 
describe rates and risk factors for specific resistant pathogens, 
such as extended-spectrum β-lactamase (ESBL)–producing 
Enterobacteriaceae or multidrug-resistant (MDR) bacteria in 
patients with cancer and HSCT recipients [10–13]. The major-
ity, however, were performed in countries with high resistance 
rates in both the hospitalized and general populations [12–14]. 
The risk of infection is influenced by local factors, among them 
prevalence of resistance, prophylactic practices, empiric treat-
ment, and antimicrobial stewardship. Only a handful of studies 
focus on children and autologous HSCT (auto-HSCT) patients 
[12, 15, 16]. This study aimed to describe resistance rates and 
risk factors in GNR bacteremia in HSCT patients, based on 
large intercontinental data.
METHODS
Study Design and Data Collection
This was a noninterventional prospective study. All patients 
in whom allogeneic HSCT (allo-HSCT) or auto-HSCT was 
performed during February 2014–May 2015 in the partic-
ipating centers were included. Data on GNR bacteremia 
episodes that occurred from the initiation of the condition-
ing regimen until 6 months after the HSCT were reported, 
including pathogen and its antimicrobial susceptibility, 
presence of risk factors, and mortality. This study was per-
formed in accordance with the appropriate regulations in 
the participating countries including approval by the ethical 
committees as required, and registered at ClinicalTrials.gov 
(NCT02257931).
The primary endpoint was to determine the proportion 
of GNRs resistant to (1) one of noncarbapenem anti-Pseu-
domonas β-lactams (noncarbapenems), including ceftazidime 
or cefepime or β-lactam/β-lactamase inhibitors (βL/βLIs); (2) 
carbapenems (one of meropenem/imipenem/doripenem); (3) 
one of fluoroquinolones; (4) MDR pathogens.
The secondary endpoints were to determine (1) proportion 
of GNRs resistant to other antibiotics; and (2) risk factors for 
resistant GNRs, as defined in the primary endpoints.
Microbiological Workup
Guidelines used to determine isolates’ susceptibility were by 
the European Committee for Antimicrobial Susceptibility 
Testing in 41 (64.1%) laboratories, the Clinical and Laboratory 
Standards Institute in 19 (29.7%) laboratories, and others in 4 
(6.2%) laboratories. Resistance to antibiotics was studied by in 
vitro sensitivity tests in the local laboratories using disk diffu-
sion in 46 of 64 (71.9%) and/or minimum inhibitory concen-
tration determination in 60 of 64 (93.8%) centers. Pathogens 
with intermediate susceptibility to antibiotics were considered 
resistant.
Definitions
An MDR GNR was defined as bacteria resistant to ≥1 agent 
in ≥3 of the following categories: (1) broad-spectrum cepha-
losporins (ceftazidime or cefepime); (2) anti-Pseudomonas βL/
βLIs; (3) carbapenems; (4) aminoglycosides; (5) fluoroquinolo-
nes. All Stenotrophomonas maltophilia strains were consid-
ered MDR. Extensively drug-resistant (XDR) bacteria defined 
if checked for susceptibility to all relevant antimicrobials and 
found nonsusceptible to ≥1 agent in all but ≤2 categories [17]. 
Infections occurring >48 hours since the hospitalization were 
considered hospital acquired.
Neutropenia was defined as an absolute neutrophil count 
<500 cells/μL.
Breakthrough bacteremia was defined as bacteremia devel-
oping during antibiotic treatment (including fluoroquinolone 
prophylaxis) provided for ≥48 hours before obtaining the blood 
culture.
Geographic regions [4] included Northwest (Austria, 
Belgium, Denmark, Finland, France, Germany, Netherlands, 
Sweden, Switzerland, United Kingdom); Southeast (Croatia, 
Cyprus, Czech Republic, Greece, Israel, Italy, Lithuania, Poland, 
Portugal, Russia, Slovakia, Spain, Turkey); other countries 
(Australia, China).
Statistical Analysis
The main characteristics of patients were reported by descrip-
tive statistics on the total of the available information.
The incidence of resistance was computed as a percentage, 
the denominator being the number of GNR pathogens and the 
numerator being the number of pathogens classified as “resist-
ant.” Early mortality was computed as a percentage of death 
occurred within 7 days after bacteremia on the episodes with a 
follow-up available at the same time.
The relationship between resistance and the following risk 
factors was investigated:
• Background: sex, age at HSCT, underlying disease, myeloab-
lative conditioning, fluoroquinolone prophylaxis.
• At the time of bacteremia: time since HSCT, duration of 
neutropenia, neutrophil recovery, duration of hospitalization, 
hospital-acquired infection, breakthrough bacteremia, graft-
vs-host disease (GVHD), acute GVHD grade II–IV, veno-
occlusive disease.
• Before bacteremia, within 1  month: urinary catheter, ≥2 
weeks of steroids, and/or other immunosuppressive treat-
ment; within 3 months: any hospitalization, hospitalization 
in the intensive care unit (ICU), any bacteremia, previous 
antibiotic therapy, and number of antibiotic classes.
Differences between groups were tested using linear or logistic 
regression models, using the generalized estimating equation 
method to take into account the dependence of observations 
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nested by patient and center [18]. The same models were used 
to study all relationships between resistance and characteristics 
or prognostic factors. Variables showing significance from the 
univariate model entered a multivariable model. The results 
obtained from these analyses are considered as exploratory and 
hypothesis-generating.
A P value <.05 was considered statistically significant. All P val-
ues are 2 sided. All the analyses were performed using the statisti-
cal software SAS version 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
Patients and Episodes
Sixty-five HSCT centers from 25 countries reported data on 655 
GNR episodes in 591 patients (1.1 episodes [range, 1–4] per 
patient) (Supplementary Table 1). Characteristics of the back-
ground patients and episodes are presented in Tables 1 and 2. 
Median time to develop GNR bacteremia was 8 (range, –15 to 
183)  days after HSCT. Fluoroquinolone prophylaxis was pro-
vided in 34 of 45 (75.6%) allo-HSCT and 22 of 49 (44.9%) auto-
HSCT adult centers, and in 6 of 24 (25.0%) allo-HSCT and 2 of 
23 (8.7%) auto-HSCT pediatric centers.
Microbiological Results
Seven hundred four GNRs included Enterobacteriaceae (514 
[73%]), nonfermentative rods (167 [24%]), and others (23 
[3%]) (Figure 1). Five hundred forty-six (83.4%) episodes were 
monomicrobial and 109 (16.6%) polymicrobial, including 
GNRs only (47 [7.2%]) or together with other pathogens (62 
[9.5%]).
Resistance Rates
Half of GNRs were resistant to fluoroquinolones and to noncar-
bapenems, 18.5% were carbapenem resistant, and 35.2% were 
MDR (Table 3). One of 73 (1.4%) Pseudomonas aeruginosa and 
4 of 14 (28.6%) Acinetobacter species were XDR. Resistance 
rates to other antibiotics are presented in Table 3.
There was no strong correlation between the rates of GNR 
bacteremia and resistance to noncarbapenems and carbapen-
ems per country; and no correlation between fluoroquinolone 
resistance and bacteremia rate per center (Supplementary 
Figure 1A–C).
Resistance Rates According to Pathogens
Fluoroquinolone resistance was significantly more frequent 
among Enterobacteriaceae (57.2% vs 30.7%; P  <  .0001); car-
bapenem resistance (50.9% vs 8.4%; P < .0001), and multidrug 
resistance (46.6% vs 31.9%; P = .001) in nonfermentative rods 
(Table 4).
Six of 31 (19%) S.  maltophilia isolates were resistant to 
trimethoprim-sulfamethoxazole.
One-third of noncarbapenem-resistant, and half of MDR path-
ogens, were carbapenem resistant (Supplementary Table 2). Six 
of 33 (18.2%) carbapenem-resistant P. aeruginosa isolates were 
susceptible to both cephalosporins and βL/βLIs (Supplementary 
Table 3); 1 of 29 (3.5%) was colistin resistant.
Among carbapenem-resistant Enterobacteriaceae, 15 of 41 
(36.6%) were resistant to amikacin, 16 of 41 (39.0%) to gen-
tamicin, 4 of 41 (9.8%) to both aminoglycosides; 32 of 40 (78%) 
to fluoroquinolones, 5 of 17 (29.4%) to tigecycline, and 6 of 33 
(18.2%) to colistin.
Resistance Rate According to Hematopoietic Stem Cell 
Transplantation Type
The resistance rates to fluoroquinolones (55.6% vs 41.4%), 
noncarbapenems (59.2% vs 36.0%), carbapenems (23.7% 
Table 1. Patient Characteristics (N = 591)
Characteristic No. (%)
Age, y, median (range) 50.9 (0.3–72.9)
Children (<18 y) 79 (13.4)
Male sex 357 (60.4)
Underlying disease
 Acute leukemia 212 (35.9)
 Lymphoma 148 (25.0)
 Plasma cell disorders 109 (18.4)
 Myelodysplastic/myeloproliferative syndromes 54 (9.1)
 Chronic leukemia 8 (1.4)
 Solid tumor 12 (2.0)
 Nonmalignant disease 48 (8.1)
Time since diagnosis of the underlying disease until HSCT, 
mo, median (range)
10.4 (1.0–256.2)
Allogeneic HSCT 360 (60.9)
Donor (allogeneic HSCT)
 Unrelated 175 (48.9)
 Matched related 114 (31.8)
 Mismatched related 69 (19.3)
Stem cell source
 Peripheral blood 451 (76.4)
 Bone marrow 101 (17.1)
 Both bone marrow and peripheral blood 10 (1.7)
 Umbilical cord blood 28 (4.7)
Conditioning (allogeneic HSCT) 
 Myeloablative 241 (68.1)
 Nonmyeloablative 113 (31.9)
Karnofsky score, median (range) 90 (0–100)
Disease status after HSCT
 Continued complete remission 317 (75.1)
 Never in complete remission 79 (18.7)
 Partial remission/stable disease 26 (6.2)
Graft-vs-host disease prophylaxis before bacteremia (allogeneic HSCT)
 Total provided 339
 Cyclosporine/tacrolimus alone 51 (15.0)
 Cyclosporine/tacrolimus + methotrexate 136 (40.1)
 Cyclosporine/tacrolimus + MMF or prednisone 117 (34.5)
 Other 35 (10.3)
Graft manipulation ex vivo (including T-cell depletion) 31 (6.2)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: HSCT, hematopoietic stem cell transplantation; MMF, mycophenolate 
mofetil. 
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Total (N = 655) P ValueAllogeneic (n = 414) Autologous (n = 241)
Neutropenia at the time of episode <500 cells/μL 296 (71.5) 199 (82.9) 495 (75.7) .005
Neutropenia at the time of episode <100 cells/μL 259 (73.4) 175 (77.8) 434 (75.1) .4
Duration of neutropenia <500 cells/μL, d, median (range) 7 (1–246) 2.5 (1–124) 5 (1–246) <.0001
Duration of neutropenia <500 cells/μL <7 d, median (range) 153 (37.0) 189 (78.8) 342 (52.3) <.0001
Duration of neutropenia <100 cells/μL, d, median (range) 5 (1–80) 2 (1–28) 3 (1–80) <.0001
Duration of neutropenia <100 cells/μL <7 d 176 (49.9) 171 (76.0) 347 (60.0) <.0001
Absolute neutrophil count recovered before bacteremia 147 (39.9) 24 (10.8) 171 (28.9) <.0001
Previous hospitalization 255 (64.6) 121 (50.4) 376 (59.2) .001
Number of hospitalization days during 3 mo preceding bacteremia, 
median (range)
38 (1–186) 15 (1–94) 30 (1–186) <.0001
Duration of current hospitalization before episode, d, median (range) 17 (0–266) 11 (0–87) 14 (0–266) <.0001
Hospital-acquired bacteremia 355 (86.8) 215 (90.7) 570 (88.2) .08
Previous ICU hospitalization 28 (6.9) 4 (1.7) 32 (4.9) .01
Bacteremia developed during hospitalization in the ICU 17 (4.2) 0 (0.0) 17 (2.6) …
Breakthrough bacteremia 303 (73.4) 98 (40.7) 401 (61.3) <.0001
 Cephalosporinsa 30 (7.3) 8 (3.3) 38 (5.8) .04
 Anti-Pseudomonas βL/βLIs 65 (15.7) 16 (6.6) 81 (12.4) .001
 Carbapenemsb 54 (13.1) 7 (2.9) 61 (9.3) <.0001
 Any β-lactamc 159 (38.5) 36 (14.9) 195 (29.8) <.0001
 Fluoroquinolones 118 (28.6) 50 (20.7) 168 (25.7) .03
 Aminoglycosides 22 (5.3) 5 (2.1) 27 (4.1) .04
 Othersd 79 (19.1) 13 (5.4) 92 (14.1) <.0001
Previous antibiotic therapy 309 (77.3) 104 (44.4) 413 (65.1) <.0001
 Cephalosporinsa 46 (11.5) 8 (3.4) 54 (8.5) .001
 Anti-Pseudomonas βL/βLIs 88 (22.0) 17 (7.3) 105 (16.6) <.0001
 Carbapenemsb 86 (21.5) 10 (4.3) 96 (15.1) <.0001
 Any β-lactamc 198 (49.5) 42 (17.9) 240 (37.9) <.0001
 Fluoroquinolones 121 (30.3) 45 (19.2) 166 (26.2) .003
 Aminoglycosides 30 (7.5) 5 (2.1) 35 (5.5) .007
 Othersd 101 (25.3) 12 (5.1) 113 (17.8) <.0001
No. of antibiotic classes of previous antibiotic therapye 
 1 antibiotic class 86 (21.4) 36 (15.3) 122 (19.2) <.0001
 2 classes 73 (18.2) 24 (10.2) 97 (15.2)
 ≥3 antibiotic categories 131 (32.6) 18 (7.7) 149 (23.4)
GVHD at the time of bacteremia (% of all allo-HSCT) 71 (17.3) …
Acute GVHD at the time of bacteremia (% of all allo-HSCT) 62 (15.1) …
Grade II–IV of acute GVHD before bacteremia (% of all allo-HSCT) 12 (4.5) …
Chronic GVHD (% of all allo-HSCT) 9 (2) …
Veno-occlusive disease at the time of bacteremia 12 (2.9) 3 (1.3) 15 (2.3) .2
Urinary catheter 38 (9.5) 7 (2.9) 45 (7.0) .007
Previous bacteremia 127 (30.7) 24 (9.9) 151 (23.1) <.0001
Recent immunosuppression 335 (81.1) 57 (23.8) 392 (60.1) <.0001
Recent steroid treatment 142 (34.5) 53 (22.3) 195 (30.0) .008
Time since HSCT, d, median (range) 11 (–15 to 183) 7 (–8 to 177) 8 (–15 to 183) <.0001
Central line infection 138 (38.4) 73 (32.3) 211 (36.1) .1
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: allo, allogeneic; auto, autologous; βL/βLI, β-lactam/β-lactamase inhibitor; GVHD, graft-vs-host disease; HSCT, hematopoietic stem cell transplant; ICU, intensive care unit.
aCephalosporins: ceftazidime, cefepime, ceftriaxone, cefotaxime, cefuroxime, cefazolin.
bCarbapenems: meropenem, imipenem, ertapenem, doripenem.
cAny β-lactam: either cephalosporin, anti-Pseudomonas βL/βLI, carbapenem, or any other β-lactam antibiotic.
dOthers: any antibiotics, excluding any β-lactam, fluoroquinolones, aminoglycosides, and prophylactic use of trimethoprim-sulfamethoxazole or dapsone.
ePrevious antibiotic exposure to the following antibiotic classes was reported: (a) any cephalosporins; (b) anti-Pseudomonas βL/βLIs; (c) carbapenems (meropenem, imipenem, ertapenem, 
doripenem); (d) fluoroquinolones (either treatment and prophylaxis); (e) aminoglycosides; (f) macrolides; (g) anti–gram-positives (glycopeptides, linezolid, daptomycin); (h) antianaerobes 
(metronidazole, clindamycin); (i) colistin; (j) tigecycline; (k) aztreonam; (l) other antibiotics.
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vs 8.9%), and multidrug resistance (43.7% vs 20.2%) were 
higher in GNRs isolated in allo-HSCT vs auto-HSCT recipi-
ents (P < .001 for all) (Table 3). Among community-acquired 
infections, there were no significant differences in fluoro-
quinolone resistance (38.8% vs 63.2%), noncarbapenem 
resistance (42.0% vs 42.1%), carbapenem resistance (15.1% 
vs 18.2%), and multidrug resistance (28.3% vs 19%) between 
allo-HSCT and auto-HSCT patients (Supplementary Tables 
4 and 5).
Resistance Rate in Children Versus Adults
Similar resistance rates were observed in children and 
adults. Only the resistance rate to fluoroquinolones and 
βL/βLIs was significantly higher in adults compared with 
children following allo-HSCT (P < .0001 and P = .048, 
respectively) (Table 3); the difference was significant in 
southeast countries only.
Geographical Distribution of Resistance Rates
There was a wide distribution in the resistance rates between 
countries (Supplementary Table  6). Resistance rates were 
more frequent in the southeast vs northwest European region: 
for noncarbapenems (266/481 [55.3%] vs 32/116 [27.6%], 
P  <  .0001); fluoroquinolones (270/496 [54.4%] vs 44/121 
[36.4%]; P  =  .002); carbapenems (109/526 [20.7%] vs 6/123 
[4.9%]; P < .0001); and multidrug resistance (201/514 [39.1%] 
vs 16/118 [13.6%]; P < .0001).
Risk Factors for Resistance
Univariate analysis of risk factors for resistant GNRs in allo-
HSCT and auto-HSCT recipients is presented in Supplementary 
Tables 4 and 5. Multivariable analysis was possible in allo-HSCT 
patients only (Table  5), as rate of resistance was low in auto-
HSCT patients.
To study the association between fluoroquinolone proph-
ylaxis and resistance, we compared resistance rates in GNRs 
cultured during the period when prophylaxis is provided (in 
neutropenic patients without empiric or targeted antibiotics 
therapy), in centers that do and do not provide prophylaxis.
The rate of fluoroquinolone-resistant GNRs was higher in 
centers providing prophylaxis (79% vs 50%, P  =  .001 in allo-
HSCT; 74% vs 25%, P < .001 in auto-HSCT). The rate of non-
carbapenem-resistant (36% vs 13%; P = .002) and MDR (35% 
Figure 1. Distribution of gram-negative pathogens. Other Enterobacteriaceae include Enterobacter spp (n = 41), Klebsiella spp (n = 24), Citrobacter spp (n = 12), Serratia spp 
(n = 6), Proteus spp (n = 3), Raoultella spp (n = 1). Other nonfermentative rods include Acinetobacter spp (n = 17), 1 each of Sphingomonas paucimobilis, Shewanella putref-
aciens, Sphingobacterium multivorum, Comamonas testosterone, Ochrobactrum spp, Ralstonia pickettii, Paracoccus yeei, Achromobacter xylosoxidans. Other gram-negative 
rods include Capnocytophaga spp (n = 8), Moraxella spp (n = 4), Aeromonas spp (n = 3), Campylobacter spp (n = 2), Rhizobium radiobacter (n = 2), and 1 each of Salmonella 
enteritidis, Haemophilus influenzae, Burkholderia cepacia, Elizabethkingia meningoseptica.
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vs 8%; P < .001) bacteria was higher in auto-HSCT patients in 
centers providing prophylaxis (Supplementary Table 7).
Outcome
The 7-day mortality was 38 of 589 (6.5%). The mortality 
according to resistance pattern was 9% vs 2% (P = .002) in 
episodes caused by noncarbapenem resistant vs sensitive 
GNRs; 18% vs 4% (P < .001) in those carbapenem resistant 
vs sensitive; and 11% vs 4% (P = .002) in MDR vs non-MDR. 
Inappropriate empiric therapy was provided for 124 of 586 
(21.2%) GNRs; being 101 of 270 (37.4%) for noncarbape-
nem resistant vs 12 of 274 (4.4%) noncarbapenem suscep-
tible bacteria; 62 of 97 (63.9%) for carbapenem resistant vs 
61 of 481 (12.7%) carbapenem susceptible; and 91 of 197 
(46.2%) for MDR vs 30 of 368 (8.1%) non-MDR GNRs (P < 
.001 for all).
DISCUSSION
In this study, we demonstrate antimicrobial susceptibility pat-
terns among GNRs causing bacteremia in HSCT patients, and 
geographical distribution of resistance in 25 countries from 
Europe, Asia, and Australia. We compare allo- and auto-HSCT 
recipients, and children and adults; and analyze risk factors for 
antibiotic resistance.
The emerging resistance challenges antibacterial prophylaxis 
policy and complicates empiric and targeted treatment choices. 
Benefit of fluoroquinolone prophylaxis was demonstrated 
in a country with a baseline resistance of approximately 20% 







GNRs in Allo-HSCT 
Adults
GNRs in Allo-HSCT 
Children 
GNRs in Auto- 
HSCT Adults 
GNRs in Auto- 
HSCT Children 
Primary endpoints
 Fluoroquinolone 325/645 (50.4) 227/408 (55.6)* 98/237 (41.4)* 205/326 (62.9)** 22/82 (26.8)** 95/228 (41.7) 3/9 (33.3)
 Noncarbapenem β-lactam 322/632 (50.9) 241/407 (59.2)* 81/225 (36.0)* 199/322 (61.8) 42/85 (49.4) 78/214 (36.4) 3/11 (27.3)
 Carbapenem 127/688 (18.5) 105/443 (23.7)* 22/245 (8.9)* 80/349 (22.9) 25/94 (26.6) 20/234 (8.6) 2/11 (18.2)




255/656 (38.9) 199/416 (47.8) 56/240 (23.3) 160/332 (48.2) 39/84 (46.4) 55/229 (24.0) 1/11 (9.1)
 Anti-Pseudomonas βL/βLI 230/627 (36.7) 177/399 (44.4) 53/228 (23.2) 146/310 (47.1)*** 31/89 (34.8)*** 51/217 (23.5) 2/11 (18.2)
 Aminoglycoside 216/662 (32.6) 162/422 (38.4) 54/240 (22.5) 135/335 (40.3) 27/87 (31.0) 51/228 (22.4) 3/12 (25.0)
 Colistin 22/358 (6.1) 18/250 (7.2) 4/108 (3.7) 12/205 (5.9) 6/45 (13.3) 4/102 (3.9) 0/6 (0.0)
 Tigecycline 15/182 (8.2) 12/124 (9.7) 3/58 (5.2) 10/109 (9.2) 2/15 (13.3) 3/58 (5.2) Not checked
Data are presented as no./No. (%). The following differences were significant: the resistance rates to fluoroquinolones, noncarbapenems, carbapenems, and multidrug resistance were 
significantly higher in GNRs isolated in allogeneic HSCT vs autologous HSCT recipients (*P < .001 for all). The rate of resistance to fluoroquinolones and anti-Pseudomonas βL/βLIs was 
significantly higher in adults vs children following allogeneic HSCT (**P < .0001 and ***P = .048, respectively).
Abbreviations: allo, allogeneic; auto, autologous; βL/βLI, β-lactam/β-lactamase inhibitor; GNR, gram-negative rod; HSCT, hematopoietic stem cell transplantation.








Resistant Aminoglycoside Colistin Tigecycline
Escherichia coli 185/283 (65.4) 140/281 (49.8) 7/301 (2.3) 81/290 (27.9) 96/298 (32.2) 0/144 2/105 (1.9)
Klebsiella pneumoniae 71/111 (63.9) 79/118 (66.9) 31/124 (25.0) 63/121 (52.1) 53/124 (42.7) 5/77 (6.5) 6/37 (16.2)
Enterobacter spp 8/39 (20.5) 19/39 (48.7) 3/41 (7.3) 9/39 (23.1) 8/41 (19.5) 0/15 1/12 (8.3)
Other Enterobacteriaceae 7/41 (17.1) 9/43 (20.9) 2/45 (4.4) 5/44 (11.4) 8/45 (17.8) 9/28 (32.1) 1/14 (7.1)
Total Enterobacteriaceae 271/474 (57.2)a 247/481 (51.4) 43/511 (8.4)a 158/494 (31.9)b 165/508 (32.5) 14/264 (5.3) 10/168 (6.0)
Pseudomonas aeruginosa 29/96 (30.2) 33/92 (35.9) 36/95 (37.9) 28/96 (29.2) 26/97 (26.8) 1/66 (1.5) Not checked
Acinetobacter baumannii 7/10 (70.0) 8/10 (80.0) 7/11 (63.6) 7/11 (63.6) 5/11 (45.5) 1/9 (11.1) 2/3 (66.6)
Stenotrophomonas maltophilia 6/22 (27.3) 14/16 (87.5) 34/34 (100) 34/34 (100) 9/9 (100) 3/10 (30.0) 0/6 
Other nonfermentative rods 4/22 (18.2) 13/20 (65.0) 5/21 (23.8) 7/22 (31.8) 5/23 (21.7) 0/1 2/2 (100)
Total nonfermentative rods 46/150 (30.7)a 68/138 (49.3) 82/161 (50.9)a 76/163 (46.6)b 45/140 (32.1) 5/86 (5.8) 4/11 (36.4)
Data are presented as no./No. (%). 
aSignificant differences between Enterobacteriaceae and nonfermentative rods (P < .0001).
bSignificant differences between Enterobacteriaceae and nonfermentative rods (P = .001).
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in GNRs from the community and medical departments [19, 
20]. In our study, 39% of GNRs causing community-acquired 
infections in allo-HSCT and 63% in auto-HSCT were fluo-
roquinolone resistant (Supplementary Tables 4 and 5). High 
rates of fluoroquinolone resistance may be the price to pay for 
lower rates of bacteremia in centers providing prophylaxis. We 
could not, however, demonstrate correlation between the rates 
of bacteremia and fluoroquinolone resistance (Supplementary 
Figure  1A). Doubts regarding the benefits of fluoroquinolone 
prophylaxis are accompanied by concern about increased rates 
of resistance to other antibiotics following exposure to fluoro-
quinolones. No association between fluoroquinolone proph-
ylaxis and the increase in MDR bacteria was shown in the 
meta-analysis of studies published up to 2005 [21]. Later pub-
lished studies, however, correlated exposure to fluoroquinolones 
with increase in infections resulting from fluoroquinolone-re-
sistant, ESBL-producing, carbapenem-resistant, and MDR 
pathogens [14, 22, 23]. In our study, in auto-HSCT patients, 
treatment in centers providing fluoroquinolone prophylaxis, 
breakthrough on fluoroquinolones, and previous exposure to 
fluoroquinolones (Supplementary Tables 5 and 7)  were asso-
ciated with resistance to noncarbapenems and MDR. The risk 
could, however, be influenced by other factors, as outpatient vs 
inpatient transplantation setting, which were not reported in 
our study. The benefits and potential risks of fluoroquinolone 
prophylaxis must be carefully assessed, especially in centers 
with high fluoroquinolone resistance rates among GNRs [24].
Empiric treatment with noncarbapenem β-lactams, or even 
carbapenems [25], can be inappropriate in centers with high 
resistance rates to these antibiotics and lead to increased mor-
tality [2, 13]. In our study, approximately 40% of communi-
ty-acquired infections were resistant to noncarbapenems and 
15%–18% to carbapenems (Supplementary Tables 4 and 5), 
probably due to acquisition of resistant bacteria during pre-
vious hospitalizations. This can lead to inappropriate empiric 
therapy. Carbapenem treatment increases the chance of pro-
viding appropriate empiric therapy, especially in southeast 
European countries. In centers with low rate of noncarbapenem 
resistance at the onset of febrile neutropenia, noncarbapenems, 
however, can still be a good option. Universal recommenda-
tions for empiric therapy are tricky because of significant geo-
graphical variations. Practical decisions on empiric therapy 
must be based on continuously updated data concerning local 
resistance patterns and bacteremia rates [26]. We are thus una-
ble to recommend the specific resistance rate threshold that 
indicates change in the empiric therapy protocol as our study 
was not designed to answer this question. While the propor-
tion of resistant bacteria was high in some centers, its impact 
on patient outcome can be low if GNR bacteremia is rare 
(Supplementary Figures 1B and 1C).
Resistance to multiple antibiotics complicates the targeted 
therapy choice. Susceptibility to tigecycline, polymyxins, fos-
fomycin, and aminoglycosides must be promptly reported 
in the centers with carbapenem-resistant infections, as some 








OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Duration of neutropenia (≥7 d) 1.79 (1.10–2.91) .02 NS NS NS
Breakthrough bacteremia on 
fluoroquinolones
7.26 (3.84–13.72) <.0001 NS NS NS
Age (adults) 3.87 (2.07–7.25) <.0001 NS NS NS
Hospital-acquired infection NS 2.09 (1.08–4.03) .029 NS NS
Breakthrough bacteremia on βL/βLI NS 2.45 (1.14–5.23) .02 NS 2.30 
(1.20–4.41)
.013
Breakthrough bacteremia on 
cephalosporins
NS 6.36 (1.68–24.07) .01 NS NS
Previous antibiotic therapy with 
other antibioticsa
NS 2.59 (1.30–5.15) .007 2.07 
(1.15–3.73)
.016 NS
Longer duration of current hospital-
ization before episode
NS NS 1.01 (1.00–1.02) .041 1.01 (1.00–1.03) .032
Current bacteremia developed 
during hospitalization in the ICU
NS NS 3.92 
(1.18–3.03)
.026 NS
Breakthrough bacteremia on 
carbapenems





Matched related vs matched unre-
lated donor
NS 1.82 (1.05–3.14) .01 NS NS
Mismatched vs matched unrelated 
donor
2.29 (1.21–4.35)
Abbreviation: βL/βLI, anti-Pseudomonas β-lactam β-lactamase inhibitor; CI, confidence interval; GNR, gram-negative rod; ICU, intensive care unit; NS, not significant; OR, odds ratio.
aOther antibiotics: any antibiotic therapy excluding β-lactams, fluoroquinolones, aminoglycosides.
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bacteria were resistant to these last-resort antibiotics in our and 
other studies [8, 27]. Eighteen percent of carbapenem-resist-
ant P.  aeruginosa was susceptible to both cephalosporins and 
βL/βLIs in our study and, in contrast to carbapenem-resistant 
Enterobacteriaceae, can be treated with these agents, especially 
administered as high-dose prolonged infusion [28].
Knowledge of pathogen-specific resistance patterns can help 
direct appropriate empiric therapy following rapid bacterial 
identification by matrix-assisted laser desorption/ionization–
time of flight (MALDI-TOF), prior to susceptibility results. 
Carbapenem monotherapy should be appropriate on identifi-
cation of non–Klebsiella pneumoniae Enterobacteriaceae, which 
are usually carbapenem susceptible. A  carbapenem/colistin 
with or without aminoglycoside combination should, however, 
be considered for K. pneumoniae or Acinetobacter pending sus-
ceptibility results, as a significant proportion of them are car-
bapenem resistant. Streamlining of antibiotic therapy, of course, 
should be performed when susceptibilities are available.
Data on resistance rates in post-HSCT children are scarce 
[12, 16, 29]. Surprisingly, resistance rates were mostly similar in 
children and in adults in our study. This differs from the lower 
resistance rates in children vs adults reported in a literature 
review of studies published until 2011 [4]. Resistance rates in 
a retrospective multicenter US study (2004–2014) in pediat-
ric allo-HSCT recipients [16] are also lower than in our study. 
Our data may indicate the trend toward increasing resistance in 
children, which emphasizes the importance of monitoring and 
prevention in this population. Fluoroquinolone prophylaxis is 
rarely provided in children, which may explain lower rates of 
fluoroquinolone resistance.
Information about resistance rates and risk factors in auto-
HSCT patients is limited and mainly concerns fluoroquinolones 
[15, 30], as bacteremia is relatively less frequent in auto-HSCT 
patients [31]. Certain factors predisposing to resistant infec-
tions—such as breakthrough bacteremia and prolonged neu-
tropenia—are less frequent in auto-HSCT vs allo-HSCT 
patients (Table 2). Although total resistance rates were higher 
in allo-HSCT patients, resistance rates in community-acquired 
infections were similar. These data reinforce the importance of 
monitoring antibiotic susceptibilities in auto-HSCT patients.
Several studies reported risk factors for cephalosporin-re-
sistant, ESBL-producing or MDR bacteria in cancer and HSCT 
patients [10, 12, 13, 16, 22, 29, 32]. Only a handful describe 
risk factors for carbapenem-resistant infections in populations 
involving but not limited to transplant patients, mainly for K. 
pneumoniae. Distinct from other studies, we found that break-
through on noncarbapenems does not predispose to carbape-
nem resistance in allo-HSCT patients [8, 14]. Noncarbapenem 
β-lactams and carbapenems are both recommended for empiric 
treatment in febrile neutropenic patients [25], half of whom 
have neither microbiological nor clinical infection. Limitation 
of carbapenem treatment, de-escalation to a narrower-spectrum 
regimen following culture results, and shortening treatment 
duration, as recommended by European Conference on 
Infections in Leukaemia guidelines, will slow development of 
carbapenem resistance without increasing mortality [26, 33].
Geographical differences in resistance rates are striking. In 
certain countries, we found higher resistance rates than those 
previously reported in the literature. In France, for example, 
34.4% of GNRs were noncarbapenem resistant, compared 
with 4% third-generation cephalosporin resistance among 
Enterobacteriaceae cultured in hematological malignancies and 
post-HSCT patients during 2003–2010, which may be explained 
by increased resistance rates over time [5]. Information about 
resistance rates in each country may, of course, be skewed by 
local epidemiology of the participating centers, and not reflec-
tive of the situation countrywide. While carbapenem-resistant 
GNRs were not reported at all in some countries, approximately 
40% of GNRs were carbapenem resistant in Russia and the 
Czech Republic, countries for which existing resistance data 
are very limited. GNR resistance rates to carbapenems in other 
studies, including HSCT patients, varied from 0% in Sweden 
[34] to 4.7%–5.8% in the United States [8, 35] to 20.9%, and even 
75.9% among K. pneumoniae, in Italy [7, 11, 14, 27]. Overall, we 
found significantly higher resistance rates in southeast as com-
pared with northwest Europe. This correlates with lower rates 
of antimicrobial resistance among the general population [36], 
which is probably explained by lower consumption of systemic 
antibacterials in the community, as well as in veterinary medi-
cine, in northwest Europe [37, 38].
The multidrug resistance rate (~30%) among Enterobac-
teriaceae and P. aeruginosa in our study was within that reported 
in cancer and HSCT patients [11–13, 35]. The rate of cotrimox-
azole resistance among S. maltophilia, the drug of choice for this 
MDR pathogen, was higher in our study (19%) compared to 
4%–10% in other studies [5, 29]. Susceptibility of Acinetobacter 
species in cancer and transplant patients has been infrequently 
studied [5, 29, 39]; XDR Acinetobacter infections were not pre-
viously reported. In our study, a third of Acinetobacter species 
were XDR.
We demonstrated higher mortality rates in infections caused 
by resistant bacteria, similar to other studies [8, 12]. Analysis 
of mortality risk factors is beyond the scope of this manuscript.
Our study has limitations. GNR resistance rates and patterns 
in our study are influenced by the epidemiology of countries 
with more participating centers. Antimicrobial susceptibil-
ity data were incomplete for some GNRs. Resistance rates to 
certain agents, such as tigecycline, could be overestimated, as 
susceptibility was likely checked in bacteria resistant to other 
treatment options, or reflecting local epidemiology. We could, 
however, demonstrate resistance rates to salvage treatments 
among their main targets, harder-to-treat pathogens. We did 
not assess important risk factors for resistance: history of recent 
residency in another country (information unavailable) and 
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prior colonization with resistant GNRs (not all participating 
centers performed colonization screening).
The study has important strengths. It is the first interconti-
nental prospective study focusing on antimicrobial resistance 
of GNRs specifically in HSCT patients, including countries 
underrepresented in the literature (eg, Russia, Switzerland), 
and countries with lower resistance rates, which makes our data 
more applicable to large-scale HSCT centers. The large sam-
ple size enables unique resistance analysis in 2 important sub-
groups—that is, auto-HSCT patients and children, about whom 
data in the literature are very scarce. It also allows comparison 
of data between auto- and allo-HSCT patients and between 
children and adults. Contrary to many studies, we analyze risk 
factors for different resistance patterns and pathogens, rather 
than focusing on specific bacteria or mechanisms.
In conclusion, the problem of antibiotic resistance is wor-
rying in all HSCT patients, including subgroups of children 
and auto-HSCT recipients. It is associated with inappropriate 
empiric therapy and increased mortality. Benefits of fluoro-
quinolone prophylaxis and the approach to empiric therapy 
should be reassessed and grounded in continuous monitoring 
of the local bacteremia rates and susceptibility data of infecting 
pathogens. Knowledge of pathogen-specific resistances enables 
early appropriate empiric therapy.
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